Novo Nordisk shares dropped 6% following a capital markets day where the firm set long-term growth targets in line with industry peers, explicitly noting these ambitions do not constitute formal financial guidance.
Novo Nordisk's long-term growth targets were in line with peers and not formal guidance, leading to a 6% share decline.
Novo Nordisk shares fell 6% on Monday after the company unveiled long-term strategic ambitions that aligned with industry peers rather than exceeding market expectations. Management clarified that the 2026-2030 growth targets are strategic goals rather than formal financial guidance, dampening investor enthusiasm.
Shares fell 6% because the company's long-term growth targets for 2026-2030 were in line with industry peers rather than exceeding them, and management clarified these are strategic ambitions rather than formal financial guidance.